Patient Perceptions of CAR-T Therapy in the USA: Findings from In-Depth Interviews
Authors:
Open Access
- 21 May 2023
- journal article
- research article
- Published by Springer Nature in Oncology and Therapy
- Vol. 11 (3) , 303-312
Abstract
Introduction Chimeric antigen receptor-T cell (CAR-T) therapy has revolutionized advanced blood cancer treatment. However, preparation, administration, and recovery from these therapies can be complex and burdensome to patients and their care partners. Utilization of an outpatient setting for CAR-T therapy administration could help improve convenience and quality of life. Methods In-depth qualitative interviews were conducted with 18 patients in the USA with relapsed/refractory multiple myeloma or relapsed/refractory diffuse large B-cell lymphoma, 10 of whom had completed investigational or commercially approved CAR-T therapy and 8 of whom had discussed it with their physicians. We aimed to better understand inpatient experiences and patient expectations regarding CAR-T therapy and to ascertain patient perspectives on the possibility of outpatient care. Results CAR-T offers unique treatment benefits, particularly high response rates with an extended treatment-free period. All study participants completing CAR-T were very positive about their inpatient recovery experience. Most reported mild-to-moderate side effects; two experienced severe side effects. All said that they would opt to undergo CAR-T therapy again. Participants felt that the primary advantage of inpatient recovery was immediate access to care and on-going monitoring. Perceived advantages of the outpatient setting were comfort and familiarity. Because immediate access to care was seen as crucial, patients recovering in an outpatient setting would seek either a direct contact person or phone line for assistance if needed. Conclusion As institutions become more experienced with CAR-T therapies, outpatient care may help reduce financial strain. Patient input can help institutions improve the outpatient experience and ensure safety and effectiveness of CAR-T programs.Keywords
This publication has 7 references indexed in Scilit:
- Chimeric Antigen Receptor T-Cell Therapies: Barriers and Solutions to AccessJCO Oncology Practice, 2022
- Overview of approved CAR‐T therapies, ongoing clinical trials, and its impact on clinical practiceeJHaem, 2021
- Worsening Financial Toxicity Among Patients Receiving Chimeric Antigen Receptor t-Cell (CAR-T) Therapy: A Mixed Methods Longitudinal StudyBlood, 2021
- Improving outcomes and mitigating costs associated with CAR T-cell therapyThe American Journal of Managed Care, 2021
- Patients’ Communication Preferences Around Cancer Symptom Reporting During Cancer Treatment: A Phenomenological StudyJournal of the Advanced Practitioner in Oncology, 2021
- Understanding Barriers to Oral Therapy Adherence in Adults With Acute Myeloid LeukemiaJournal of the Advanced Practitioner in Oncology, 2020
- Snowball Sampling: A Purposeful Method of Sampling in Qualitative ResearchStrides in Development of Medical Education, 2017